HOSPITAL UNIVERSITARIO RUBER
Departamento
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (22)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
2023
2022
-
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139
-
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review
Breast Cancer Research and Treatment, Vol. 194, Núm. 1, pp. 1-11
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Practice Choices in Targeted Intrathecal Drug Delivery: An Online Survey Conducted by the Polyanalgesic Consensus Committee
Neuromodulation
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
A Systematic Literature Review of Peripheral Nerve Stimulation Therapies for the Treatment of Pain
Pain Medicine (United States), Vol. 21, Núm. 8, pp. 1590-1603
-
How to Restart the Interventional Activity in the COVID-19 Era: The Experience of a Private Pain Unit in Spain
Pain Practice, Vol. 20, Núm. 8, pp. 820-828
-
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
British Journal of Cancer
2019
-
Breast cancer
Nature Reviews Disease Primers, Vol. 5, Núm. 1
2018
-
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357
2017
-
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544
-
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)
Breast Cancer Research and Treatment
-
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
European Journal of Cancer, Vol. 76, pp. 205-215
-
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Breast Cancer Research and Treatment, Vol. 165, Núm. 2, pp. 329-341
-
The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks
Neuromodulation, Vol. 20, Núm. 2, pp. 155-176
2016
-
Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
Cancer and Metastasis Reviews, Vol. 35, Núm. 2, pp. 323-332
-
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
SpringerPlus, Vol. 5, Núm. 1